Last edition
News about "Sun Pharmaceutical Industries "
Sun Pharma Presents LEQSELVITM Data at 2024 Fall Clinical Dermatology Conference
LEQSELVI data presented at Fall Clinical includes pooled long-term results from open-label extension (OLE) studies showing ongoing and clinically meaningful improvements in scalp hair regrowth in adults with AA taking LEQSELVI for up to 68 weeks.
Sun Pharmaceutical Industries | 28/10/2024 | By Aishwarya | 101
Sun Pharma Launches a Tedizolid Phosphate Tablets in India
STARIZO (Tedizolid Phosphate) is a novel, oxazolidinone-class antibacterial, used to treat Acute Bacterial Skin and Skin Structure Infection (ABSSSI).
Sun Pharmaceutical Industries | 26/08/2024 | By Aishwarya | 160
Sun Pharma to Invest Upto USD 15 Million for 5 Percent Stake in Pharmazz
Sun Pharma described the investment as strategic, noting it will gain exclusive rights to market and distribute Pharmazz’s drug, Sovateltide, in certain emerging markets.
Sun Pharmaceutical Industries | 17/08/2024 | By Aishwarya | 193
Sun Pharma Gets US FDA Approval for LEQSELVI for Treatment of Severe Alopecia Areata
Sun Pharmaceutical Industries Ltd. has announced that the US Food and Drug Administration (FDA) has approved LEQSELVI (deuruxolitinib) 8 mg tablets for the treatment of adults with severe alopecia areata.
Sun Pharmaceutical Industries | 26/07/2024 | By Aishwarya | 561
Sun Pharmaceutical Industries and Moebius Medical have presented data demonstrating the durability of pain relief achieved in symptomatic knee OA patients through 26 weeks post injection of MM-II.
Sun Pharmaceutical Industries | 15/06/2024 | By Aishwarya | 324
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy